Articles tagged "Rejection"

2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
A. Rizvi¹, M. Kueht², S. Hussain³, J. Fair², R. Ramirez⁴, A. Gamilla-Crudo⁵, M. Mujtaba⁵
¹Internal Medicine, Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX, ²Surgery, University of Texas Medical Branch, Galveston, TX, ³University of Texas Medical Branch, Houston, TX, ⁴Surgery, University of Texas Medical Branch at Galveston, Galveston, TX, ⁵University of Texas Medical Branch, Galveston, TX
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…
2022 American Transplant Congress
Month 1 Donor Derived Cell Free DNA Levels Predict Future Kidney Transplant Rejection
B. M. Kinsella¹, K. Guo¹, C. Rebello¹, L. Zhao¹, S. Park², J. Friedewald¹
¹Northwestern University, Chicago, IL, ²Transplant Nephrology, Northwestern University, Chicago, IL
*Purpose: The purpose of this study was to determine if donor-derived cell-free DNA (dd-cfDNA) can be used one-month post-transplant to predict later allograft rejection.*Methods: Retrospective…
2022 American Transplant Congress
Impact of Delayed Graft Function in Donation After Circulatory Death Kidney Transplantation
J. Mello Offerni¹, H. Brar¹, D. Lee¹, M. Levine², M. Mandurah¹, S. Rim¹, A. Sener¹, P. Luke¹
¹Urology, Western University, London, ON, Canada, ²Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada
*Purpose: Donation after circulatory death (DCD) has been associated with higher rates of delayed graft function (DGF) when compared to donation after brain death (DBD).…
2022 American Transplant Congress
DEPTOR: A Novel Endothelial-Specific Regulator of Cell-Intrinsic Anti-Inflammation Following Transplantation
C. Testini¹, S. Bose¹, K. Liu¹, S. Kong¹, E. Flynn¹, M. Miovski¹, J. Leyva-Rangel¹, M. Laplante², J. Wedel¹, D. M. Briscoe¹
¹Boston Children's Hospital and Harvard Medical School, Boston, MA, ²Laval University, Quebec, QC, Canada
*Purpose: Recent studies have highlighted a paradigm whereby the maintenance of normal tissue homeostasis and the prevention of chronic inflammation is dependent on the active…
2022 American Transplant Congress
A Single-Center’s Outcomes of Combined Heart-Liver Transplantation
R. W. Lincoln¹, K. Kalvakuri², A. Guha², A. Bhimaraj², E. E. Suarez², A. Saharia³, C. M. Mobley³, F. Amirkhosravi³, J. Krisl¹
¹Pharmacy, Houston Methodist Hospital, Houston, TX, ²DeBakey Heart and Vascular Associates, Houston Methodist Hospital, Houston, TX, ³Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…
2022 American Transplant Congress
Circulating Donor-Derived Cell-Free DNA: A Novel Non-Invasive Biomarker for Immune Surveillance in Vascularized Composite Allotransplantation
W. J. Rifkin¹, J. Trilles¹, P. S. Rabbani¹, O. C. Onuh¹, B. E. Gelb², D. J. Ceradini¹, E. D. Rodriguez¹
¹Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, ²Transplant Institute, NYU Langone Health, New York, NY
*Purpose: The purpose of this study is to evaluate whether circulating donor-derived cell-free DNA (dd-cfDNA) could be used as a noninvasive biomarker to detect rejection…
2022 American Transplant Congress
Study Of Matrix Metalloproteinase (mmp) And Tissue Inhibitors Of Metalloproteinase (timp) Gene Polymorphisms In Renal Allograft Outcome
J. P. Tom¹, J. Singh¹, A. Sharma², R. Aggarwal¹, R. Nada³, R. Ramachandran⁴, S. Anand¹, R. Minz¹
¹Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India, ³Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, ⁴Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
*Purpose: Our study aimed to find a role, if any, of functional gene polymorphisms of MMP and their inhibitors- TIMP in renal allograft outcome.*Methods: The…
2022 American Transplant Congress
Evaluation of Post-Transplant Angiotensin II Type 1 Receptor Antibodies, Donor-Derived Cell-Free DNA, and Rejection in Heart Transplant Recipients
B. Agegnehu¹, S. Sterling¹, R. Winstead¹, I. Tchoukina²
¹Pharmacy, VCU Health System, Richmond, VA, ²Advanced Heart Failure and Transplant Cardiology, VCU Health System, Richmond, VA
*Purpose: There is limited evidence evaluating the relationship between angiotensin II type 1 receptor antibodies (AT1R-Abs), donor-derived cell-free DNA (dd-cfDNA), and rejection in heart transplant…
2022 American Transplant Congress
Dynamic Changes in Titer and Specificity Autoantibodies in Chronic Bm12 to B/6 Kidney Rejection
I. Sayin¹, D. Yin¹, D. Ghosh², M. Clark², A. Chong¹
¹Department of Surgery, University of Chicago, Chicago, IL, ²Department of Medicine, University of Chicago, Chicago, IL
*Purpose: Loss of autoreactive B cell tolerance and production of non-HLA autoantibodies have been observed in patients undergoing chronic rejection, however, how autoreactive B cells…
2022 American Transplant Congress
A Sustained Injury Response by Regulatory T Cells (Treg) Contributes to Fibrosis to Promote Chronic Rejection After Heart Transplantation
J. Bou Saba¹, L. Fan¹, X. Zhang¹, T. Li¹, L. R. Mathews¹, G. Dwyer², E. Colon², M. J. Calderon³, K. E. Helfrich³, M. A. Ross³, S. C. Watkins³, H. Turnquist¹
¹Surgery, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ²Immunology, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ³Cell Biology, University of Pittsburgh, Center for Biologic Imaging, Pittsburgh, PA
*Purpose: Chronic rejection (CR) results from the development of immunosuppressant-resistant allograft vasculopathy and fibrosis and remains a leading cause of recipient death one-year post-heart transplant…